Daptomycin for Injection
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacteremia
Conditions
Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious
Trial Timeline
Dec 6, 2018 → Apr 7, 2020
NCT ID
NCT03643952About Daptomycin for Injection
Daptomycin for Injection is a phase 2 stage product being developed by Merck for Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT03643952. Target conditions include Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03643952 | Phase 2 | Completed |
Competing Products
9 competing products in Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin + Comparator | Merck | Approved | 85 |
| Vancomycin + Daptomycin | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Cefazolin IV + Linezolid IV + Vancomycin (IV) | Pfizer | Phase 3 | 76 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| ceftobiprole medocaril | Basilea Pharmaceutica | Phase 2 | 47 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| AP-SA02 | Armata Pharmaceuticals | Phase 1/2 | 33 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |